DK2231708T3 - Midler mod pemphigus, som indeholder antistoffer mod fas-liganden - Google Patents
Midler mod pemphigus, som indeholder antistoffer mod fas-liganden Download PDFInfo
- Publication number
- DK2231708T3 DK2231708T3 DK08859792.7T DK08859792T DK2231708T3 DK 2231708 T3 DK2231708 T3 DK 2231708T3 DK 08859792 T DK08859792 T DK 08859792T DK 2231708 T3 DK2231708 T3 DK 2231708T3
- Authority
- DK
- Denmark
- Prior art keywords
- tyr
- fasl
- antibody
- pemphigus
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Materials For Medical Uses (AREA)
- Luminescent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (5)
1
1. Antistof valgt blandt: (i) et monoklonalt antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæde-re-gion, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: CDR Hl i As« Tyr Jfp m C!y $S03 ID »:!}, |th| CPU Tyr L#y Tyr Rrp øiy øty Lwi Tyr Thr Am Tyr .Asn Gly Lys Ph® Lp Oly mm ID NO: 2% (ρ§| CDR H3i Tyr Arg Asp Tyr Asp Tyr Ak IM Asp fyr C» 10 NO: 3| og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er fis) CDR Li: Lp Sir Thr Lys Sir Lm Lm Am Sir Asp Oty Pha ?hr Tyr lm Oly fSEO m NO: 4% COR 12: Uy ¥a! Sar Asn Arg Pha Sir fSEO ID NO: S}, 1¾) CDR L3: Rim Oln Sir Asn Tyr Lay Fro Lau Thr (SEQ ID NO; S) til anvendelse til forebyggelse og/eller behandling af pemphigus.
2. Antistof valgt blandt: (i) et monoklonalt antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæde-re-gion, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: fa:} CDR HI: 1¾ Tyr Rrø Mm »(SEQ ID NO; 7% (ih) CDR H2: Mil Ife Tyr Thr Asp Thr Gly Oto Frø Sir Tyr Ala Glo Glo PheLpCI fSEO ID NO: 8|, CDR H3; Pha Tyr Trp Asp Tyr Fhi Asp Tyr f SEG ID NO: S) og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er 2 COR LI ; te® Mm S&f Wn Aip> Ilt Tyr t&y Asfi (SEQ ID NO; 1D|t €01¾ Lt; Tyr ?hf S«r Arg Le« His Ser (SEO !D ICfc 11}, (*&) CDR L3: Gin ONi Giy S#f Thr im Dm Trp Jht (SEO ID NO; 12) til anvendelse til forebyggelse og/eller behandling af pemphigus.
3. Antistof til anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor antistoffet eller et antigenbindende fragment deraf er valgt blandt et delvist eller helt humaniseret antistof, et delvist eller helt humaniseret enkeltkædet antistof eller et fragment deraf.
4. Antistof til anvendelse ifølge et hvilket som helst af de foregående krav i en kombinationsbehandling sammen med mindst én yderligere behandling, som er effektiv mod pemphigus.
5. Antistof til anvendelse ifølge krav 4 i kombination med mindst ét yderligere immunosuppressivt lægemiddel, navnlig med mindst ét yderligere steroid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1314707P | 2007-12-12 | 2007-12-12 | |
| US5180108P | 2008-05-09 | 2008-05-09 | |
| PCT/EP2008/010597 WO2009074339A1 (en) | 2007-12-12 | 2008-12-12 | Remedies for pemphigus containing anti fas ligand antobodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2231708T3 true DK2231708T3 (da) | 2015-07-13 |
Family
ID=40565064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08859792.7T DK2231708T3 (da) | 2007-12-12 | 2008-12-12 | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110038867A1 (da) |
| EP (1) | EP2231708B1 (da) |
| JP (1) | JP2011506371A (da) |
| KR (1) | KR20100130584A (da) |
| CN (1) | CN101918449A (da) |
| AU (1) | AU2008334912B8 (da) |
| BR (1) | BRPI0820877A2 (da) |
| CA (1) | CA2708790A1 (da) |
| DK (1) | DK2231708T3 (da) |
| ES (1) | ES2538489T3 (da) |
| HR (2) | HRP20150409T1 (da) |
| HU (1) | HUE025525T2 (da) |
| IL (1) | IL206280A0 (da) |
| MX (1) | MX2010006450A (da) |
| NZ (2) | NZ602964A (da) |
| PL (1) | PL2231708T3 (da) |
| PT (1) | PT2231708E (da) |
| RU (1) | RU2558260C2 (da) |
| SI (1) | SI2231708T1 (da) |
| WO (1) | WO2009074339A1 (da) |
| ZA (1) | ZA201004271B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5773882B2 (ja) | 2008-12-12 | 2015-09-02 | ピンチェル ソチエタ・レスポンサビリタ・リミタータＰｉｎＣｅｌｌ ｓｒｌ | 抗ＦａｓＬリガンド抗体を含有する天疱瘡用治療薬 |
| RU2013130324A (ru) * | 2011-01-10 | 2015-02-20 | ОПКО Фармасьютикалз, ЛЛС | Суррогаты антигенов при аутоиммунных заболеваниях |
| CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| CN104645303B (zh) * | 2015-03-23 | 2017-12-08 | 重庆妙坤生物科技有限责任公司 | 一种治疗类天疱疮的中药组合物 |
| IL298438A (en) | 2015-09-17 | 2023-01-01 | Immunogen Inc | Medical combinations containing anti-folr1 immune conjugates |
| KR102380150B1 (ko) * | 2016-03-08 | 2022-03-29 | 얀센 바이오테크 인코포레이티드 | Gitr 항체, 방법, 및 용도 |
| EA037973B1 (ru) * | 2016-10-12 | 2021-06-18 | Янссен Байотек, Инк. | Антитела к gitr, способы и применение |
| EP4441095A1 (en) * | 2021-12-01 | 2024-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing anti-cd95l monoclonal antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0872488B1 (en) * | 1995-03-20 | 2006-05-24 | Ko Okumura | MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME |
| CN1196733A (zh) * | 1995-06-30 | 1998-10-21 | 持田制药株式会社 | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| AU725329B2 (en) * | 1996-09-02 | 2000-10-12 | Ko Okumura | Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand |
| IL164011A0 (en) * | 2002-03-21 | 2005-12-18 | Lilly Co Eli | Antagonistic anti-hfas ligand human antibodies andfragments thereof |
| FR2933264B1 (fr) * | 2008-06-25 | 2012-10-26 | Actimagine | Procede d'authentification d'un utilisateur d'un service sur terminal mobile. |
-
2008
- 2008-12-12 ES ES08859792.7T patent/ES2538489T3/es active Active
- 2008-12-12 RU RU2010128556/10A patent/RU2558260C2/ru not_active IP Right Cessation
- 2008-12-12 MX MX2010006450A patent/MX2010006450A/es active IP Right Grant
- 2008-12-12 WO PCT/EP2008/010597 patent/WO2009074339A1/en active Application Filing
- 2008-12-12 KR KR1020107015082A patent/KR20100130584A/ko not_active Application Discontinuation
- 2008-12-12 JP JP2010537326A patent/JP2011506371A/ja active Pending
- 2008-12-12 NZ NZ602964A patent/NZ602964A/xx not_active IP Right Cessation
- 2008-12-12 AU AU2008334912A patent/AU2008334912B8/en not_active Ceased
- 2008-12-12 PT PT88597927T patent/PT2231708E/pt unknown
- 2008-12-12 NZ NZ586148A patent/NZ586148A/xx not_active IP Right Cessation
- 2008-12-12 CN CN2008801241807A patent/CN101918449A/zh active Pending
- 2008-12-12 US US12/747,765 patent/US20110038867A1/en not_active Abandoned
- 2008-12-12 PL PL08859792T patent/PL2231708T3/pl unknown
- 2008-12-12 SI SI200831424T patent/SI2231708T1/sl unknown
- 2008-12-12 BR BRPI0820877A patent/BRPI0820877A2/pt not_active IP Right Cessation
- 2008-12-12 EP EP08859792.7A patent/EP2231708B1/en active Active
- 2008-12-12 CA CA2708790A patent/CA2708790A1/en not_active Abandoned
- 2008-12-12 DK DK08859792.7T patent/DK2231708T3/da active
-
2009
- 2009-12-14 HU HUE09801201A patent/HUE025525T2/en unknown
-
2010
- 2010-06-10 IL IL206280A patent/IL206280A0/en unknown
- 2010-06-17 ZA ZA2010/04271A patent/ZA201004271B/en unknown
-
2015
- 2015-04-13 HR HRP20150409TT patent/HRP20150409T1/hr unknown
- 2015-04-28 HR HRP20150457TT patent/HRP20150457T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100130584A (ko) | 2010-12-13 |
| MX2010006450A (es) | 2010-12-15 |
| RU2010128556A (ru) | 2012-01-20 |
| EP2231708A1 (en) | 2010-09-29 |
| HRP20150409T1 (hr) | 2015-05-22 |
| PT2231708E (pt) | 2015-07-30 |
| ZA201004271B (en) | 2011-03-30 |
| RU2558260C2 (ru) | 2015-07-27 |
| HRP20150457T1 (hr) | 2015-06-05 |
| PL2231708T3 (pl) | 2015-09-30 |
| WO2009074339A1 (en) | 2009-06-18 |
| NZ586148A (en) | 2012-11-30 |
| IL206280A0 (en) | 2010-12-30 |
| AU2008334912B2 (en) | 2013-09-26 |
| JP2011506371A (ja) | 2011-03-03 |
| BRPI0820877A2 (pt) | 2017-06-06 |
| CA2708790A1 (en) | 2009-06-18 |
| HUE025525T2 (en) | 2016-05-30 |
| US20110038867A1 (en) | 2011-02-17 |
| SI2231708T1 (sl) | 2015-06-30 |
| EP2231708B1 (en) | 2015-04-08 |
| AU2008334912A1 (en) | 2009-06-18 |
| AU2008334912B8 (en) | 2013-10-24 |
| CN101918449A (zh) | 2010-12-15 |
| NZ602964A (en) | 2013-06-28 |
| ES2538489T3 (es) | 2015-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2231708T3 (da) | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden | |
| US9114131B2 (en) | Antibody targeting osteoclast-related protein Siglec-15 | |
| US9902782B2 (en) | Anti-human tie-2 antibody | |
| MX2013005477A (es) | Variantes de fc silenciosas de los anticuerpos anti-cd40. | |
| DK2376536T3 (da) | Midler mod pemphigus, som indeholder antistoffer mod fas-liganden | |
| AU2023213334A1 (en) | Anti-human cxcl1 antibody |